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Abstract A glycoprotein (Mr =43000) from horseshoe crab 
hemocytes with antimicrobial activity against Gram-negative 
bacteria was purified. The internal peptide sequences coincided 
exactly with the deduced amino acid sequence of a cDNA clone, 
designated limnius factor D, which was isolated by screening a 
hemocyte cDNA library with an anti-human plasminogen 
antibody. The open reading frame codes for a precursor of 
factor D of 394 amino acid residues, including an NH2-terminal 
signal sequence. The COOH-terminal domain of factor D has 
significant sequence homology with the catalytic domain of 
mammalian serine proteases, in particular with human tissue 
plasminogen activator (32% identity), except for the substitution 
of Ser of the active site triad to Gly. Factor D has a unique NH2- 
terminal domain with weak sequence homology with part of the 
mammalian interleukin-6 receptor ~-chain. Factor D is likely to 
have an important role in host defense mechanisms. 
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are considered to be important for host defense in engulfing 
and killing invading microbes, in addition to preventing leak- 
age of hemolymph. We purified and characterized serine pro- 
tease zymogens participating in the clotting cascade [1-5], 
protease inhibitors [7-10], lectins [11,12], and antibacterial 
substances [13,14], all of which are stored in the two types 
of granules. In the course of studies on these host defense 
molecules, a 43-kDa protein was co-purified uring isolation 
procedures of factor G, a (1,3)-[3-o-glucan-sensitive serine pro- 
tease zymogen [15]. The partial amino acid sequence of the 43- 
kDa protein indicated identity to the protein product of a 
cDNA clone, designated limulus factor D, which was isolated 
by screening a hemocyte cDNA library with an anti-human 
plasminogen antibody. We now report that the 43-kDa pro- 
tein is a serine protease homologue with antimicrobial ctivity 
and probably belongs to the family of serprocidins [16,17]. 
2. Materials and methods 
I. Introduction 
Invertebrates have characteristic host defense systems differ- 
ing from those of the mammalian immune system and can 
eliminate foreign substances and invading microorganisms 
even without immunoglobulins. In the horseshoe crab, one 
of the major defense systems is carried by hemolymph, which 
contains two types of hemocytes, granular and non-granular 
cells [1-5]. The granular cells comprise 99% of total hemo- 
cytes, which contain two populations of secretory granules in 
the cytosol known as large and small granules [6]. The cells 
are highly sensitive to bacterial endotoxins, lipopolysacchar- 
ides (LPS), a major outer membrane component of Gram- 
negative bacteria, and respond by degranulating and secreting 
granular components from large and small granules after LPS 
stimulation, the result being clot formation. These responses 
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2.1. Materials 
The lysate of hemocytes from Japanese horseshoe crabs (Tachypleus 
tridentatus) was prepared as described [18] and large and small gran- 
ules of hemocytes were separated using our documented methods [19]. 
2.2. Antimicrobial ctivity 
Antimicrobial ctivity was assayed as described previously [14]. 
2.3. Peptide preparation, sequencing, and amino acid analysis 
The purified protein was reduced, S-alkylated with iodoacetamide, 
then digested with lysylendopeptidase (E/S=I/100, w/w) and the re- 
suiting peptides were separated by reversed-phase HPLC [14]. Amino 
acid sequences of the purified peptides were determined using Applied 
Biosystems gas-phase quencer model 473A. For amino acid analysis, 
samples were hydrolysed in6 M HC1 in evacuated and sealed tubes at 
ll0°C for 20 h. The hydrolysates were analyzed using a PICO-TAG 
system (Waters-Millipore, Milford, MA). 
2.4. Computer-assisted analysis of sequence data 
The sequence of factor D was compared with all entries in the 
SWlSS-PROT Database (release 17, February 1996) with the Gene 
Works system (IntelliGenetics, Mountain View, CA). 
2.5. SDS-PA GE and immunoblotting 
SDS-PAGE was performed in 12% slab gels according to Laemmli 
[20]. The gels were stained with Coomassie brilliant blue R-250. An 
antiserum against factor D was raised in rabbits, using a synthetic 
adjuvant, TiterMax (Vaxcel, GA), and given intradermally [9]. For 
immunoblotting, els were transferred to nitrocellulose membranes 
and the membranes were treated with the antiserum and incubated 
with horseradish peroxidase-conjugated goatanti-rabbit IgG and vis- 
ualized with 4-chloro-l-naphthol [8]. 
2.6. cDNA cloning of factor D 
One million independent clones of the ~gt 11 cDNA library were 
screened with anti-human plasminogen antibody as described pre- 
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Fig. 1. SDS-PAGE of purified 43-kDa protein and its subcellular lo- 
calization. A: SDS-PAGE under nonreducing (NR) and reducing 
(R) conditions. B: Large granules (L, 1.7 p.g), small granules (S, 1.3 
~tg), and factor D (D, 1.4 jig) were subjected to SDS-PAGE, under 
reducing conditions, and factor D was identified by immunoblot- 
ring. 
viously [21]. One positive clone with a 1.3-kb insert was subcloned 
into the EcoRI site of pBluescript II SK + and the nucleotide sequence 
on both strands was determined [8]. 
3. Results 
3.1. Purification of  a 43-kDa protein 
A 43-kDa protein was isolated from a subfraction obtained 
during purification procedures of horseshoe crab factor G. 
Factor G has been purified from hemocyte lysate by three 
steps of chromatography - dextran sulfate-Sepharose CL- 
6B, Con A-Sepharose, and Sephacryl $200 [15]. A major 
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peak with fractions 30-45 on the gel filtration of Sephacryl 
$200 contained a protein with an apparent molecular weight 
of 43 000 on SDS-PAGE as a main component (data not 
shown). The pooled fraction was dialyzed against 50 mM 
sodium acetate, pH 5.5, containing 0.05 M NaC1, and applied 
to a CM Sepharose column (3 × 20 cm), equilibrated with the 
same buffer. After washing with the equilibration buffer, the 
43-kDa protein was eluted with a linear gradient of 0.05-0.5 
M NaC1 in the same buffer and it gave a single protein band 
on SDS-PAGE, under reducing and non-reducing conditions 
(Fig. 1A). Thus, the 43-kDa protein from 100 g of hemocytes 
(wet weight) was purified with a yield of about 5 mg. 
3.2. Peptide and nucleotide sequencing of the 43-kDa protein 
No major PTH-amino acid derivative was obtained by Ed- 
man degradation of the purified 43-kDa protein, an event 
suggesting a blocked NH2-terminus. Peptides derived from 
the 43-kDa protein were prepared by lysylendopeptidase di- 
gestion, and nine were sequenced. The resulting sequence data 
coincided exactly with the deduced amino acid sequence of a 
cDNA clone, designated limulus factor D, which was isolated 
by screening a hemocyte cDNA library with anti-human plas- 
minogen antibody (Fig. 2). The cDNA included 1329 nucleo- 
tides with an open reading frame of 1182 nucleotides and 
encoded a protein of 394 amino acid residues, including an 
NH2-terminal signal sequence with a typical hydrophobic 
core. A peptide with the amino acid composition correspond- 
ing to the NH2-terminal Gln TM to Lys 61 was also obtained 
from the digest, and the result suggest that the a-amino group 
of NH2-terminal Gln 19 in the mature protein had been cy- 
clized (data not shown). There was a potential N-linked gly- 
cosylation site at Asn 2s° and amino acid sequence analysis of 
the peptide yielded no PTH-Asn at that position, indicating 
that Asn 2s° had been modified by the N-linked sugar chain. In 
fact, amino acid analysis on the mature 43-kDa protein indi- 
cated the presence of glucosamine r sidues (data not shown). 
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Fig. 2. Nucleotide and deduced amino acid sequences of factor D. The putative cleavage site for the signal peptide is indicated by the arrow- 
head. The N-glycosylation site is indicated by the closed circle. The amino acid residues corresponding to the catalytic triad of serine protease 
are circled. The stop codon is indicated by the asterisk. Amino acid residues confirmed by sequencing the isolated peptides are underlined. 
Numbering of amino acid residue starts with the initiation Met. 
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Fig. 3. Alignment of the COOH-terminal domain of factor D with catalytic domains of human serine proteases (A) and alignment of the NH~- 
terminal region of factor D with those of mammalian i terleukin-6 (IL6) receptor t~-chains (B). A: The protease domains of tissue plasminogen 
activator (tPA-ser), plasmin (Plm-ser), complement factor Cls (Cls-ser), and thrombin (Thr-ser) are compared with that of the COOH-terminal 
domain of factor D (Factor D-ser). Residues identical to factor D are boxed. Residue numbering starts with the first amino acid residue of 
each catalytic domain and the residues that form the catalytic site in serine proteases are indicated by asterisks. B: Residue numbering starts 
with the first amino acid residue of each mature protein. 
3.3. Sequence similarity to other proteins 
A search of SWISS-PROT showed a striking similarity of 
the COOH-terminal domain of limulus factor D (262 residues) 
to the catalytic domain of mammalian serine proteases, except 
for substitution of a catalytic residue corresponding to the 
active site Ser 195 (chymotrypsinogen numbering) to Gly (Fig. 
3A). This pseudo-serine protease domain of factor D was 
more closely related to the catalytic domains of human tissue 
plasminogen activator [22] (31.7% identity) and also human 
plasmin [23] (29.4%) than to those of human Cls  [24] (27.9%) 
and human thrombin [25] (23.3%). Among four serine pro- 
teases involved in the horseshoe crab coagulation cascade, the 
sequence of factor D showed the highest similarity with that 
of the clotting enzyme [26] (31.7%). 
On the other hand, the NH2-terminal domain of factor D 
(114 residues) had weak sequence homology with the NH2- 
terminal region, an immunoglobulin-like domain, of mamma- 
lian interleukin-6 receptor a-chains in mouse [27], rat [28], and 
human [29] (Fig. 3B). 
3.4. Antibacterial activity of factor D 
Factor D had significant antibacterial activity against 
S. Kawabata et al.IFEBS Letters 398 (1996) 14~150 
Table 1 
Antimicrobial ctivity of factor D 
Bacteria Factor D IC5o (Ixg/ml) 
Gram-negative bacteria 
Escherichia coli (clinical isolate) 36 
Escherichia coli 09; K39 (K-) 290 
Escherichia eoli 09; K39 (K +) 480 
Salmonella typhimurium LT2 (S) 40 
Salmonella minnesota R595 (Re) 70 
Klebsiella pneumoniae (clinical isolate) NI 
Gram-positive bacteria 
Staphylococcus aureus NI 
NI, no inhibition at 400 I.tg/ml. 
Gram-negative bacteria, including several Eseherichia coli 
strains, Salmonella typhimurium LT2 (S), and Salmonella min- 
nesota R595 (Re), but not the Gram-positive Staphylococcus 
aureus. The 50% inhibitory concentration (ICs0) of factor D 
for growth of these bacteria was determined using the micro- 
plate culture method [14], as summarized in Table 1. 
3.5. Subcellular localization of  factor D 
Antiserum raised against purified factor D was used to 
identify the subcellular localization in hemocytes. Isolated 
large and small granules from hemocytes were subjected to 
SDS-PAGE, under reducing conditions for immunoblotting 
[8]. The anti-factor D antiserum recognized the 43-kDa factor 
D in the extract of large granules (Fig. 1B). However, immu- 
noreactive materials in the extract of small granules with this 
antiserum were never observed, indicating that factor D lo- 
cates in the large granule. 
4. Discussion 
The established sequence of limulus factor D indicates that 
the COOH-terminal domain of 262 residues has a significant 
sequence homology with the catalytic domain of serine pro- 
teases, except for an amino acid substitution. The higher se- 
quence similarity of factor D to proteases found in the fibri- 
nolytic system is consistent with its cross-reactivity against 
anti-human plasminogen antibody. Substitution of Set in the 
active site triad to Gly occurs in the serine protease-like do- 
main, despite conservation f two other catalytic residues (His 
and Asp), thereby indicating no endogenous proteolytic activ- 
ity of factor D. In fact, the isolated factor D shows no amb 
dase activity toward the synthetic peptide substrates tested 
(data not shown). Based on the predicted isulfide locations 
of factor D shown in Fig. 3A, the NH2-terminal and the 
COOH-terminal domains may be linked by a single interchain 
disulfide bridge, and the peptide bond cleavage between 
Arg 132 and Ile 133 is presumed to form a two-chain factor D. 
However, at present we have no evidence for a specific pro- 
tease that converts the single-chain factor D to the two-chain 
form. 
Human neutrophils contain serine proteases (cathepsin G 
and elastase) and a serine protease homologue (azurocidin) in 
the azurophil granule, a specialized lysosome of the cells, in 
addition to defensins [16,17]. These have antimicrobial ctiv- 
ities, and hence are referred to as 'serprocidins', a family of 
serine proteases and serine protease homologues with antimi- 
crobial activity. Azurocidin also shows no demonstrable pro- 
tease activity, as might be predicted from the two amino acid 
substitutions, His to Ser and Ser to Gly, in the active site of 
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the molecule. Factor D, in this sense, may belong to serpro- 
cidins, although the sequence homology between the COOH- 
terminal domain of factor D and azurocidin is only 25.6%. 
Factor D is present in large granules of hemocytes and may 
be co-released with other defense molecules stored in granules, 
in response to external stimulation of LPS. Factor D has a 
unique NH2-terminal domain with weak homology to part of 
the interleukin 6 receptor c~-chain, suggesting an important 
functional role of factor D in host defense systems, in addition 
to its antimicrobial ctivity. The role of limulus factor D in 
host defense mechanisms is the subject of ongoing study. 
Acknowledgements: We thank C. Yano for excellent technical assist- 
ance in amino acid and sequence analyses and S. Matsumura for 
secretarial services. M. Ohara provided helpful comments on the 
manuscript. This work was supported by Grants-in-Aid for Scientific 
Research from the Ministry of Education, Science, Sports and Culture 
of Japan. 
References 
[1] Iwanaga, S., Miyata, T., Tokunaga, F. and Muta, T. (1992) 
Thromb. Res. 68, 1-32. 
[2] Iwanaga, S. (1993) Curr. Opin. Immunol. 5, 74-82. 
[3] Iwanaga, S., Muta, T., Shigenaga, T., Miura, Y., Seki, N., Saito, 
T. and Kawabata, S (1994) Ann. NY Acad. Sci. 712, 102-116. 
[4] Iwanaga, S., Muta, T., Shigenaga, T., Seki, N., Kawano, K., 
Katsu, T. and Kaw.abata, S. (1994) in: Antimicrobial Peptides 
(Ciba Foundation Symposium 186) pp. 160-175, John Wiley and 
Sons, New York. 
[5] Kawabata, S., Muta, T. and Iwanaga, S. (1996) in: New Direc- 
tions in Invertebrate Immunology (S6derh/ill, K., lwanaga, S. 
and Vasta, G.R., Eds.), pp. 255-283, SOS Publications, Fair 
Haven. 
[6] Toh, Y., Mizutani, A., Tokunaga, F., Muta, T. and Iwanaga, S. 
(1991) Cell Tissue Res. 266, 137 147. 
[7] Nakamura, T., Hirai, T., Tokunaga, F., Kawabata, S. and Iwa- 
naga, S. (1987) J. Biochem. (Tokyo) 101, 1297 1306. 
[8] Miura, Y., Kawabata, S. and Iwanaga, S. (1994) J. Biol. Chem. 
269, 542 547. 
[9] Miura, Y., Kawabata, S., Wakamiya, Y., Nakamura, T. and 
Iwanaga, S. (1995) J. Biol. Chem. 270, 558 565. 
[10] Lal Agarwala, K., Kawabata, S., Miura, Y., Kuroki, Y. and 
Iwanaga, S. (1996) J. Biol. Chem. (in press). 
[11] Okino, N., Kawabata, S., Saito, T., Hirata, M., Takagi, T. and 
Iwanaga, S. (1995) J. Biol. Chem. 270, 31008-31015. 
[12] Saito, T., Kawabata, S., Hirata, M. and Iwanaga, S. (1995) 
J. Biol. Chem. 270, 14493-14499. 
[13] Nakamura, T., Furunaka, H., Miyata, T., Tokunaga, F., Muta, 
T., Iwanaga, S., Niwa, M., Takao, T. and Shimonishi, Y. (1988) 
J. Biol. Chem. 263, 16709-16713. 
[14] Saito, T, Kawabata, S., Shigenaga, T., Cho, J., Nakajima, H., 
Hirata, M. and Iwanaga, S. (1995) J. Biochem. (Tokyo) 117, 
1131 1137. 
[15] Muta, T., Seki, N., Takaki, Y., Hashimoto, R., Oda, T., Iwana- 
ga, A., Tokunaga, F. and lwanaga, S. (1995) J. Biol. Chem. 270, 
892-897. 
[16] Pohl, J., Pereira H.A., Martin, N.M. and Spitznagel J.K. (1990) 
FEBS Lett. 272, 200-204. 
[17] Gabay, J.E. and Almeida, R.P. (1993) Curr. Biol, 5, 97 102. 
[18] Nakamura, T., Morita, T. and Iwanaga, S. (1986) Eur. J. Bio- 
chem. 154, 511-521. 
[19] Shigenaga, T., Takayenoki, Y., Kawasaki, S., Seki, N., Muta, T., 
Toh, Y., Ito, A. and Iwanaga, S. (1993) J. Biochem. (Tokyo) 114, 
307-316. 
[20] Laemmli, U.K. (1970) Nature 227, 680-685. 
[21] Tokunaga, F., Muta, T., Iwanaga, S., Ichinose, A., Davie, E.W., 
Kuma, K. and Miyata, T. (1993) J. Biol. Chem. 268, 262-268. 
[22] Pennica, D., Holmes, W.E., Kohr, W.J., Harkins, R.N., Vehar, 
G.A., Ward, C.A., Bennett, W.F., Yelverton, E., Seeburg, P.H., 
Heyneker, H.L., Goeddel, D.V. and Collen, D. (1983) Nature 
301, 214-221. 
150 
[23] Sottrup-Jensen, L., Claeys, H., Zajdel, M., Petersen, T.E. and 
Magnusson, S. (1978) Prog. Chem. Fibrinol. Thrombol. 3, 191- 
209. 
[24] Mckinnon, C.M., Carter, P.E., Smyth, S.J., Dunbar, B. and 
Fothergill, J.E. (1987) Eur. J. Biochem. 169, 547-553. 
[25] Degen, S.J.F., MacGillivary, R.T.A. and Davie, E.W. (1983) 
Biochemistry 22, 2087-2097. 
[26] Muta, T., Hashimoto, R., Miyata, T., Nishimura, H., Toh, Y. 
and Iwanaga, S. (1990) J. Biol. Chem. 265, 22426-22433. 
S. Kawabata et al./FEBS Letters 398 (1996) 146-150 
[27] Sugita, T., Totuka, T., Saito, M., Yamasaki, K., Taga, T., Hi- 
rano, T. and Kishimoto, T. (1990) J. Exp. Med. 171, 2001-2009. 
[28] Baumann, M., Baumann H. and Fey, G.H. (1990) J. Biol. Chem. 
265, 19853-19862. 
[29] Yamasaki, K., Taga, T., Hirata, Y., Yawata, H., Kawanishi, Y., 
Seed, B., Taniguchi, T., Hirano T. and Kishimoto, T. (1988) 
Science 241, 825-828. 
